top of page
Browse by category
Search
Fractyl unveils promising preclinical data demonstrating safety and feasibility of local delivery of RJVA-001 Rejuva Smart GLP-1 Pancreatic Gene Therapy
Fractyl Health has presented new data from its preclinical Rejuva Smart GLP-1 pancreatic gene therapy program in a poster titled,...
German Real-World Registry shows meaningful and sustained weight loss for at least one year after a single Revita endoscopic procedure
Fractyl Health has announced new weight maintenance and blood sugar clinical results from the Company’s German Real-World Registry for...
FDA grants Breakthrough Device Designation for Fractyl’s Revita in weight maintenance for people with obesity who discontinue GLP-1s
The FDA has granted Breakthrough Device Designation (BDD) for Fractyl Health’s Revita System for use in the maintenance of weight loss...
Revita results in weight loss and sustained weight maintenance without weight regain at one year
The latest weight maintenance data from a pooled analysis of patients enrolled in Revita (Fractyl Health) clinical studies across the EU...
Rejuva GLP-1-based pancreatic gene therapy candidate results in greater weight loss vs. semaglutide
Fractyl Health has revealed preclinical findings from its Rejuva gene therapy platform at the European Association for the Study of...
Browse by tag
bottom of page